Company Dossier · Health Care
Charles River Laboratories
- S&P 500
- Russell 1000
What Charles River Laboratories is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 27, 2026: $4.00 billion, down 0.7% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 27, 2026: $0.37 billion, down 36% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 27, 2026: $0.21 billion, about level with a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 27, 2025: $0.36 billion.SEC EDGAR filings (10-K)
- Long-term debt issued in the fiscal year to December 27, 2025: $1.23 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (August 5, 2026): sentiment 0.70 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.80 of 1.Palanor Discourse
- Guidance in the last 90 days: 3 outlook figures raised, 1 lowered, 0 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 18, 2026): 3 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $25.7 million on the open market.SEC Form 4
- 571 institutional managers reported a position at June 30, 2026 (+10 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 19 (16 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →What Charles River Laboratories is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Steady · Mixed
Expanding ↔ Retrenching
Steady
- Capital spending66th pct
- Debt raised88th pct
- Buybacks vs capex48th pct
- Hiring filings12th pct
- Deals and private raises49th pct
- Patent publications6th pct
Confident ↔ Hedging
Mixed
- Call sentiment82nd pct
- Call confidence73rd pct
- Guidance changes33rd pct
- Risk factors added15th pct
- Insider open-market trades62nd pct
- + Call sentiment
- − Risk factors added
- + Call confidence
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver84th pct
- Stress filings48th pct
Credit
How these are built →Charles River Laboratories's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$2.6B
- Due within a year $0.0B
- Longer term $2.6B
- Default point $1.3B (short + ½ long)
Finance leases included · Jun 27, 2026 filing
Bonds priced, last 12 months
None
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
In the news
Headlines that name Charles River Laboratories, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralA Look at Charles River Laboratories International Inc (CRL) After 7.1% Gain -- GF Value $194.24 vs Price $310.77
gurufocus.com · via Marketaux · Oct 5, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 21, 2026LobbyingLobbying report (CAPITOL HILL CONSULTING GROUP)third_quarter 2026 · $0.1 million
- Jul 21, 2026LobbyingLobbying report (CAPITOL HILL CONSULTING GROUP)second_quarter 2026 · $0.1 million
- Jun 23, 2026Patent
- May 11, 20268-KShareholder vote resultsItem 5.07
- May 11, 20268-KDirector or officer changeItem 5.02
- Apr 21, 2026LobbyingLobbying report (CAPITOL HILL CONSULTING GROUP)first_quarter 2026 · $0.1 million
- Apr 10, 2026LobbyingLobbying report (BGR GOVERNMENT AFFAIRS)first_quarter 2026
- Mar 3, 2026Patent
- Feb 18, 20268-KDirector or officer changeItem 5.02
- Feb 18, 202610-KAnnual report (10-K)3 risk factors added, 0 removed
- Feb 10, 2026Patent
- Feb 6, 2026LobbyingLobbying report (CAPITOL HILL CONSULTING GROUP)first_quarter 2026
- Feb 3, 2026Patent
- Jan 20, 2026LobbyingLobbying report (BGR GOVERNMENT AFFAIRS)fourth_quarter 2025 · $0.1 million
- Jan 9, 20268-KDirector or officer changeItem 5.02
- Oct 20, 2025LobbyingLobbying report (BGR GOVERNMENT AFFAIRS)third_quarter 2025 · $0.1 million
- Sep 19, 20258-KDirector or officer changeItem 5.02
- Sep 16, 20258-KDirector or officer changeItem 5.02
- Jul 21, 2025LobbyingLobbying report (BGR GOVERNMENT AFFAIRS)second_quarter 2025 · $0.1 million
- May 23, 20258-KDirector or officer changeItem 5.02
- May 23, 20258-KShareholder vote resultsItem 5.07
- May 7, 20258-KMaterial agreement signedItem 1.01
- May 7, 20258-KDirector or officer changeItem 5.02
- Mar 25, 2025PatentPatent granted: CHO HOST CELL PROTEIN ASSAYUS 12259383
- Feb 19, 202510-KAnnual report (10-K)1 risk factors added, 0 removed
- Feb 14, 202410-KAnnual report (10-K)1 risk factors added, 1 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Mettler Toledo MTD | $4.1B | $0.9B | Jun 30, 2026 |
| Illumina, Inc. ILMN | $4.5B | $0.9B | Jun 28, 2026 |
| Waters Corporation WAT | $4.6B | — | Jul 4, 2026 |
| Bio-Rad Laboratories BIO | $2.6B | $0.3B | Jun 30, 2026 |
| Agilent Technologies A | $7.4B | $1.3B | Jul 31, 2026 |
| Bio-Techne TECH | $1.2B | $0.3B | Jun 30, 2026 |
| IQVIA IQV | $16.6B | $2.1B | Mar 31, 2026 |
| Align Technology ALGN | $4.1B | $0.6B | Jun 30, 2026 |